SEC Comment Letter for Arbutus Biopharma Corp (ABUS) (CIK 0001447028) (ABUS) — Sep 3, 2020
Arbutus Biopharma Corp (ABUS) (CIK 0001447028)
Date: Sept. 3, 2020 · CIK: 0001447028 · Accession: 0000000000-20-008331
AI Filing Summary & Sentiment
File numbers found in text: 333-248467
Letter
United States securities and exchange commission logo September 3, 2020 David Hastings Chief Financial Officer Arbutus Biopharma Corporation 701 Veterans Circle Warminster, Pennsylvania 18974 Re:Arbutus Biopharma Corporation Registration Statement on Form S-3 Filed August 28, 2020 File No. 333-248467 Dear Mr. Hastings: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Courtney Lindsay at (202) 551-7237 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steve Abrams
Show Raw Text
United States securities and exchange commission logo
September 3, 2020
David Hastings
Chief Financial Officer
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, Pennsylvania 18974
Re:Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed August 28, 2020
File No. 333-248467
Dear Mr. Hastings:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Courtney Lindsay at (202) 551-7237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steve Abrams